Clinical Trials Logo

Acute Ischemic Stroke clinical trials

View clinical trials related to Acute Ischemic Stroke.

Filter by:

NCT ID: NCT05376098 Recruiting - Clinical trials for Acute Ischemic Stroke

An fNIRS Study of Motor Cortical Activation in Stoke Patients

Start date: February 1, 2022
Phase:
Study type: Observational

The investigators evaluate the activation and connectivity of patients' motor regions in the acute phase of ischemic stroke by fNIRS.

NCT ID: NCT05367362 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

The study will be a prospective, randomized, double- blinded placebo, single center pilot clinical trial. Patients with acute ischemic stroke due to large vessel occlusion undergoing endovascular thrombectomy will be included. The treatment group will receive 200 mg intravenous/oral minocycline hydrochloride in addition to endovascular thrombectomy for a total of 21 days. The control group will receive standard medical and endovascular care along with a similar looking placebo. Patients will be randomized to the treatment or control group by the Pharmacy eliminating the selection bias. The patient and evaluator will be blind to the allocation of patients further minimizing the bias. Through randomization we expect to achieve two groups that are comparable in their baseline clinical characteristics.

NCT ID: NCT05363397 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Safety and Tolerability of AZD6482 in Reperfusion for Stroke

STARS
Start date: October 1, 2022
Phase: Phase 2
Study type: Interventional

STARS is a prospective, multicentre, open-label, dose escalation, Phase IIa study to assess the safety and tolerability of AZD6482, an adjuvant antiplatelet therapy, in patients with AIS. Acute ischaemic stroke (AIS) is caused by a severe blockage of an artery leading to immediate reduced blood flow to part of the brain. Standard therapies target the blocked artery by either dissolving the blockage or removing the blockage. However, even after successful treatment, re-blockage of arteries can occur. The use of an antiplatelet therapy, AZD6482, in addition to standard therapies offers the possibility of improved restoration of blood flow and reduced rates of artery re-blockage.

NCT ID: NCT05345366 Completed - Clinical trials for Acute Ischemic Stroke

The Correlation Between CITED2 and Collateral Circulation in Acute Ischemic Stroke

Start date: November 1, 2020
Phase:
Study type: Observational

Evaluating the collateral circulation of acute ischemic stroke (AIS) mainly depends on the imaging examination. At present, there is no effective and sensitive biomarker for collateral circulation. Thus, the research objective was to evaluate the predicting role of the CBP/P300-interacting transactivator with Glu/Asp-rich C-terminal domain 2 Ratio (CITED2) from peripheral blood mononuclear cells in the collateral circulation of AIS. We classified the AIS patients into two groups (the good collateral group and the poor collateral group) by DWI-ASPECTS score. The western blot was applied to test the protein expression of vascular endothelial growth factor (VEGF) and CITED2. Then, we collected other clinical data. Binary logistic regression analysis between collateral circulation and clinical data was performed. Finally, Receiver operating characteristic (ROC) curve analysis was used to explore the predictive value of the CITED2.

NCT ID: NCT05342038 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Study on the Efficacy and Safety of T-02 for the Treatment for Acute Ischemic Stroke

T-02
Start date: April 22, 2022
Phase: N/A
Study type: Interventional

To examine the revascularization efficacy and safety of T-02 and its associated performance characteristics in treatment of appropriately selected subjects experiencing an acute ischemic stroke when the treatment is initiated within 24 hours after last seen well under the current guideline, and to generate hypotheses to be confirmed in subsequent confirmatory clinical investigations

NCT ID: NCT05326932 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Large Artery Occlusion Treated in Extended Time With Mechanical Thrombectomy Trial

LATE-MT
Start date: July 30, 2022
Phase: N/A
Study type: Interventional

A multi-center, prospective, randomized, open-label, adaptive group sequential designed, blinded endpoint assessment (PROBE) clinical trial of endovascular treatment among selected AIS

NCT ID: NCT05323266 Not yet recruiting - Clinical trials for Sleep Apnea, Obstructive

Ventilation Modalities and Acute Ischemic Stroke

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Acute ischemic stroke is the second leading cause of death and disability, and it is also one of the main reasons for the high cost of health care. The major risk factors for stroke are hypertension, atrial fibrillation, and smoking, which are the main intervention targets for primary stroke prevention. Although these recognized risk factors have been adequately treated, there are also significant differences in stroke incidence and outcome in the population. Sleep apnea is a common complication of acute ischemic stroke, characterized by upper airway obstruction and obstructive sleep apnea. Nowadays, more studies are currently investigating CPAP to promote long-term neurological recovery, improve the ability to perform activities of daily living, and reduce the recurrence of cardiovascular disease in stroke patients. However, 25%-50% of patients with sleep apnea will refuse or be intolerant of ventilation with CPAP. High-flow nasal cannula (HFNC) therapy is a revolutionary non-invasive respiratory support option that is widely used in NICU worldwide. There is currently a significant increase in the rate of pulmonary infections in stroke patients presenting with sleep apnea, leading to an increase in both length and cost of hospitalization, yet there are no better preventive measures available in the clinic. This project aims to investigate the value of different ventilation methods in reducing the rate of pulmonary infections and tracheal intubation in stroke patients. This project is a prospective randomized cohort study, collecting patients with acute ischemic stroke in the intensive care unit of the Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology from 2022.05.01 to 2023.04.30. Patients who met the inclusion criteria were subjected to polysomnography on the first day of admission, and those diagnosed with sleep apnea according to the diagnostic criteria for sleep apnea were randomly grouped. Patients were given different forms of oxygen therapy, such as conventional oxygen therapy (nasal cannula oxygenation), nasal continuous positive airway pressure (nCPAP), and HFNC oxygen therapy. After one week of observation, we evaluated whether there were differences in the rate of tracheal intubation and pulmonary infection between the groups, as well as the length of hospitalization, hospital costs, and neurological recovery.

NCT ID: NCT05310630 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

Study to Evaluate The Safety and Efficacy of Balovaptan in Patients With Acute Ischemic Stroke at High Risk of Developing Malignant Brain Edema

Start date: March 31, 2022
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the safety, efficacy, and pharmacokinetics of balovaptan compared with placebo in participants with acute ischemic stroke (AIS) at risk of developing malignant cerebral edema (MCE)

NCT ID: NCT05300997 Not yet recruiting - Atrial Fibrillation Clinical Trials

Translational Immunodiagnostics in Stroke (TrImS)

TrImS
Start date: May 1, 2022
Phase:
Study type: Observational [Patient Registry]

In adult patients presenting to emergency departments within 24 hours of symptom onset with suspected acute stroke, we aim: 1. to identify early brain- and pathology-specific circulating, whole blood, plasma and serum panorOmic biomarkers that enable early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis. 2. to identify early brain- and pathology-specific, panorOmic biomarkers in saliva that enable early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis. 3. to derive biomarker platforms of models for early acute stroke detection, diagnosis, dynamics, differentiation, monitoring, prediction and prognosis 4. to validate these models in independent and external datasets

NCT ID: NCT05295173 Not yet recruiting - Clinical trials for Acute Ischemic Stroke

A Study of r-PA Treating Patients With Acute Ischemic Stroke

Start date: March 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of recombinant human tissue plasminogen kinase derivatives for injection and alteplase in the treatment of patients with acute ischemic stroke within 4.5 hours.